Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor

Human Gene Therapy

Volumn 11, Issue 6, 2000, Pages 839-850

  Chang, Alfred E ^a,d   Li, Qiao ^a   Bishop, D Keith ^a   Normolle, Daniel P ^b   Redman, Bruce D ^a   Nickoloff, Brian J ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TUMOR VACCINE; VIRUS VECTOR;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MOLONEY LEUKEMIA ONCOVIRUS; TUMOR CELL; VACCINATION; VIRUS PARTICLE;

ADULT; AGED; CANCER VACCINES; CELL TRANSPLANTATION; DENDRITIC CELLS; FEMALE; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPH NODES; MELANOMA; MIDDLE AGED; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TUMOR CELLS, CULTURED;

MOLONEY MURINE LEUKEMIA VIRUS; ONCOVIRINAE;

EID: 0034630307     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015455     Document Type: Article

References (35)

1. ARCA, M.J., KRAUSS, J.C., ARUGA, A., CAMERON, M.J., SHU, S., and CHANG, A.E. (1996a). Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 3, 39-47.
2. ARCA, M.J., KRAUSS, J.C., STROME, S.E., CAMERON, M.J., and CHANG, A.E. (1996b). Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol. Immunother. 42, 237-245.
3. ARUGA, A., ARUGA, E., TANIGAWA, K., BISHOP, D.K., SONDAK, V.K., and CHANG, A.E. (1997). Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159, 664-673.
4. ASHER, A.L., MULÉ, J.J., KASID, A., RESTIFO, N.P., SALO, J.C., REICHERT, C.M., JAFFE, G., FENDLY, B., KRIEGLER, M., and ROSENBERG, S.A. (1991). Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146, 3227-3247.
5. CERIO, R., GRIFFITHS, C.E.M., COOPER, K.D., NICKOLOFF, B.J., and HEADINGTON, J.T. (1989). Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br. J. Dermatol. 121, 421-433.
6. CHANG, A.E., SONDAK, V.K., BISHOP, D.K., NICKOLOFF, B.J., MULLIGAN, R.C., and MULÉ, J.J. (1996). Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Gene Ther. 7, 773-792.
7. CHANG, A.E., ARUGA, A., CAMERON, M.J., SONDAK, V.K., NORMOLLE, D.P., FOX, B.A., and SHU, S.Y. (1997). Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15, 796-807.
8. CHOU, T., BERTERA, S., CHANG, A.E., and SHU, S.Y. (1988a). Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol. 141, 1775-1781.
9. CHOU, T., CHANG, A.E., and SHU, S. (1988b). Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: Culture requirements and characterization of immunologic specificity. J. Immunol. 140, 2453-2461.
10. COLOMBO, M.P., FERRARI, G., STOPPACCIARO, A., PARENZA, M., RODOLFO, M., MAVILIO, P., and PARMIANI, G. (1991). Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinom a in vivo. J. Exp. Med. 173, 889-897.
11. CONNOR, J, BANNERJI, R., SAITO, S., HESTON, W., FAIR, W., and GILBOA, E. (1993). Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med. 177, 1127-1134.
12. DONAHUE, R.E., WANG, E.A., STONE, D.K., KAMEN, E., WONG, G.G., SEHGAL, P.K., NATHAN, D.G., and CLARK, S.C. (1986). Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature (London) 321, 872-875.
13. DRANOFF, G., JAFFE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D.M., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
14. ELLEM, K.A., O'ROURKE, M.G., JOHNSON, G.R., PARRY, G., MISKO, I.S., SCHMIDT, C.W., PARSONS, P.G., BURROWS, S.R., CROSS, S., FELL, A., LI, C.L., BELL, J.R., DUBOIS, P.J., MOSS, D.J., GOOD, M.F., KELSO, A., COHEN, L.K., DRANOFF, G., and MULLIGAN, R.C. (1997). A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 44, 10-20.
15. FEARON, E.R., PARDOLL, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
16. FIELDS, R.C., SHIMIZU, K., and MULÉ, J.J. (1998). Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 95, 9482-9487.
17. GANSBACHER, B., ZIER, K., DANIELS, B., CRONI, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
18. GEIGER, J.D., WAGNER, P.D., CAMERON, M.J., SHU, S., and CHANG, A.E. (1993). Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother. 13, 153-65.
19. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
20. HEADINGTON, J.T. (1993). Dermal dendrocytes. In Dermal Immune System. B.J. Nickoloff, ed. CRC Press, Boca Raton, FL, pp. 8-23.
21. LEONG, S.P., ENDERS-ZOHR, P., ZHOU, Y.M., STUNTEBECK, S., HABIB, F.A., ALLEN, R.E.J., SAGEBIEL, R.W., GLASSBERG, A.B., LOWENBERG, D.W., and HAYES, F.A. (1999). Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J. Immunol. 22, 166-174.
22. + T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin. Cancer Res. 5, 461-469.
23. METCALF, D., BEGLEY, C.G., and WILLIAMSON, D.J. (1987). Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp. Hematol. 15, 1-9.
24. MORTON, D.L., WEN, D.R., WONG, J.H., ECONOMOU, J.S., CAGLE, L.A., STORM, F.K., FOSHAG, L.J., and COCHRAN, A.J. (1992). Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127, 392-399.
25. NAGAI, E., OGAWA, T., KIELIAN, T., IKUBO, A., and SUZUKI, T. (1998). Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunol. Immunother. 47, 72-80.
26. NESTLE, F.O., ZHENG, X.G., THOMPSON, C.B., TURKA, L.A., and NICKOLOFF, B.J. (1993). Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151, 6535-6545.
27. NESTLE, F.O., BURG, G., FAH, J., and NICKOLOFF, B.J. (1997a). In vivo and in vitro characterization of human tumor associated dendritic cells: Deficiency in T cell co-stimulatory molecules and impaired antigen-presenting function. Am. J. Pathol. 150, 641-651.
28. NESTLE, F.O., BURG, G., and NICKOLOFF, B.J. (1997b). Tumor associated dendritic cells possess markedly diminished levels of T cell co-stimulatory molecules CD80 and CD86. Am. J. Pathol. 150, 641-652.
29. PEREZ-DIEZ, A., BUTTERFIELD, L.H., LI, L., CHAKRABORTY, N.G., ECONOMOU, J.S., and MUKHERJI, B. (1998). Generation of CD8+ and CD4+ T-cell to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 58, 5305-5309.
30. ROSENBERG, S.A., SPIESS, P., and LAFRENIERE, P. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321.
31. SALLUSTO, P., and LANZAVECCHIA, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118.
32. SHU, S.Y., CHOU, T., and SAKAI, K. (1989). Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J. Immunol. 143, 740-748.
33. TANIGAWA, K., YU, H., SUN, R., NICKOLOFF, B.J., and CHANG, A.E. (2000). Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol. Immunother. 48, 635-643.
34. WITMAR-PACK, M.D., OLIVIER, W., VALINSKY, J., SCHULER, G., and STEINMAN, R.M. (1987). Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J. Exp. Med. 166, 1484-1498.
35. YOSHIZAWA, H., CHANG, A.E., and SHU, S. (1991). Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147, 729-737.